Characterization of Biocompatible Scaffolds Based on Gelatin and Hyaluronic Acid for Fibroblasts Culture
Source abstract
Abstract
Gelatin/hyaluronic acid (Gel/HA) scaffolds were prepared by using the freeze-drying method after crosslinking with 1-ethyl-(3-3-dimethylaminopropyl) carbodiimide (EDC). The porous structure was characterized by scanning electron microscopy (SEM), and the wettability of Gel/HA film was also studied by measuring their contact angle. The biological behaviour of the scaffolds was analyzed by studying the cell behaviour using a fibroblast cell line and standard biological MTT test. The results showed that the scaffold had an inter-connected pore structure with a sufficient pore size for use as a support for the growth of fibroblasts. The contact angle decreased with increasing HA content, whereas the cell attachment and proliferation improved with decreasing HA content. Confocal laser scanning microscopy (CLSM) demonstrated a normal cell distribution and proliferation on the porous Gel/HA scaffolds.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Bone Tissue Engineering Materials · Electrospun Nanofibers in Biomedical Applications · Collagen: Extraction and Characterization
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Key Laboratory of Theoretical Chemistry and Molecular Simulation of Ministry of Education, School of Chemistry and Chemical Engineering, Hunan University of Science and Technology, Xiangtan, P.R. China
Department of Orthopaedics, the Second Xiangya Hospital, Central South University, Changsha, P.R. China
References (20)
Show source-provided references
1. 10.1016/S0142-9612(00)00121-610.1016/S0142-9612(00)00121-6 ↗
2. 10.1016/S0142-9612(00)00126-510.1016/S0142-9612(00)00126-5 ↗
3. 10.1016/j.biomaterials.2004.03.01310.1016/j.biomaterials.2004.03.013 ↗
4. 10.1002/jbm.a.3109510.1002/jbm.a.31095 ↗
5. 10.1007/s10529-006-9219-z10.1007/s10529-006-9219-z ↗
6. 10.1146/annurev.cellbio.23.090506.12333710.1146/annurev.cellbio.23.090506.123337 ↗
7. 10.1007/s00586-007-0443-610.1007/s00586-007-0443-6 ↗
8. 10.1016/j.ijpharm.2008.11.00810.1016/j.ijpharm.2008.11.008 ↗
9. 10.1016/S0142-9612(02)00549-510.1016/S0142-9612(02)00549-5 ↗
10. 10.1016/j.actbio.2008.06.00810.1016/j.actbio.2008.06.008 ↗
11. 10.1016/j.carres.2007.08.02110.1016/j.carres.2007.08.021 ↗
12. 10.1002/(SICI)1097-4652(199905)179:2<142::AID-JCP4>3.0.CO;2-Q10.1002/(SICI)1097-4652(199905)179:2<142::AID-JCP4>3.0.CO;2-Q ↗
13. 10.1002/(SICI)1097-4636(199711)37:2<243::AID-JBM14>3.0.CO;2-F10.1002/(SICI)1097-4636(199711)37:2<243::AID-JBM14>3.0.CO;2-F ↗
14. 10.1016/S0142-9612(99)00036-810.1016/S0142-9612(99)00036-8 ↗
15. 10.1007/s10856-007-3334-910.1007/s10856-007-3334-9 ↗
16. 10.1002/jbm.b.3008710.1002/jbm.b.30087 ↗
17. 10.1002/jbm.a.1022310.1002/jbm.a.10223 ↗
18. 10.1002/jbm.a.3181610.1002/jbm.a.31816 ↗
19. 10.1007/BF0321837810.1007/BF03218378 ↗
20. 10.1002/jbm.82028021110.1002/jbm.820280211 ↗